{"id":9919,"date":"2004-04-03T09:05:10","date_gmt":"2004-04-03T09:05:10","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9919"},"modified":"2014-05-22T18:11:15","modified_gmt":"2014-05-22T18:11:15","slug":"11th-conference-on-retroviruses-and-opportunistic-infections-croi-2","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9919","title":{"rendered":"11th Conference on Retroviruses and Opportunistic Infections (CROI)"},"content":{"rendered":"<p><strong>8-11 February 2004, San Francisco<\/strong><\/p>\n<p><strong>About 3,500 doctors, researchers, healthcare workers, journalists and community advocates attended the 11th Conference on Retroviruses and Opportunistic Infections held in San Francisco from 8-11 February, 2004. This meeting is one of the most important annual meetings, and is prioritised by many researchers as the first choice platform for their research.<\/strong><\/p>\n<p>There is always more to report from this meeting than we can summarise in HTB and links to recommended sites that provide a wide range of additional reports are included in our \u2018On The Web\u2019 section at the end of HTB.<\/p>\n<p>Many of the overview presentations are available as audio and video webcasts from the conference website, and include slide presentations from these talks, and is accessible from both Mac and PCs. The conference website also has access to searchable abstracts online and many of the full posters are posted as pdf files.<\/p>\n<p><a href=\"http:\/\/www.retroconference.org\/\">http:\/\/www.retroconference.org<\/a><\/p>\n<p>Unless stated otherwise, all references in the following articles are to the Programme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco.<\/p>\n<p>Reports in this issue include:<\/p>\n<ul>\n<li><a title=\"Permanent link to Drug levels can persist for more than two weeks after stopping efavirenz\" href=\"https:\/\/i-base.info\/htb\/3261\" rel=\"bookmark\">Drug levels can persist for more than two weeks after stopping efavirenz<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Race affects absorption and clearance of efavirenz\" href=\"https:\/\/i-base.info\/htb\/3265\" rel=\"bookmark\">Race affects absorption and clearance of efavirenz<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation\" href=\"https:\/\/i-base.info\/htb\/7122\" rel=\"bookmark\">COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Treatment with generics: tolerability, safety and resistance\" href=\"https:\/\/i-base.info\/htb\/2781\" rel=\"bookmark\">Treatment with generics: tolerability, safety and resistance<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination\" href=\"https:\/\/i-base.info\/htb\/9911\" rel=\"bookmark\">Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome\" href=\"https:\/\/i-base.info\/htb\/9908\" rel=\"bookmark\">Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T\" href=\"https:\/\/i-base.info\/htb\/9906\" rel=\"bookmark\">Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Studies of new pipeline drugs\" href=\"https:\/\/i-base.info\/htb\/9902\" rel=\"bookmark\">Studies of new pipeline drugs<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Little benefit seen for treatment during acute infection\" href=\"https:\/\/i-base.info\/htb\/9900\" rel=\"bookmark\">Little benefit seen for treatment during acute infection<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Summary of resistance studies at Retrovirus\" href=\"https:\/\/i-base.info\/htb\/9896\" rel=\"bookmark\">Summary of resistance studies at Retrovirus<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Update on peripheral neuropathy in HIV-infection\" href=\"https:\/\/i-base.info\/htb\/9891\" rel=\"bookmark\">Update on peripheral neuropathy in HIV-infection<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Smoking marijuana provides analgesic effect on HIV neuropathy\" href=\"https:\/\/i-base.info\/htb\/9889\" rel=\"bookmark\">Smoking marijuana provides analgesic effect on HIV neuropathy<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure\" href=\"https:\/\/i-base.info\/htb\/9887\" rel=\"bookmark\">Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Low-dose rHGH maintains reductions in abdominal fat for 60 weeks\" href=\"https:\/\/i-base.info\/htb\/9884\" rel=\"bookmark\">Low-dose rHGH maintains reductions in abdominal fat for 60 weeks<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Rosiglitazone shows no benefit for lipoatrophy\" href=\"https:\/\/i-base.info\/htb\/9881\" rel=\"bookmark\">Rosiglitazone shows no benefit for lipoatrophy<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Hypertension related to HAART in HIV-positive women\" href=\"https:\/\/i-base.info\/htb\/9878\" rel=\"bookmark\">Hypertension related to HAART in HIV-positive women<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Testosterone therapy for women with low androgen levels or body weight\" href=\"https:\/\/i-base.info\/htb\/9876\" rel=\"bookmark\">Testosterone therapy for women with low androgen levels or body weight<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Nevirapine, pregnancy and adverse events\" href=\"https:\/\/i-base.info\/htb\/9874\" rel=\"bookmark\">Nevirapine, pregnancy and adverse events<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Prior nevirapine exposure for pregnant women can contribute to treatment failure\" href=\"https:\/\/i-base.info\/htb\/9872\" rel=\"bookmark\">Prior nevirapine exposure for pregnant women can contribute to treatment failure<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Conflicting findings with HAART use in pregnancy and prematurity\" href=\"https:\/\/i-base.info\/htb\/9869\" rel=\"bookmark\">Conflicting findings with HAART use in pregnancy and prematurity<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Antiretrovirals, mode of delivery and transmission risk\" href=\"https:\/\/i-base.info\/htb\/9867\" rel=\"bookmark\">Antiretrovirals, mode of delivery and transmission risk<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Tenofovir studies in children\" href=\"https:\/\/i-base.info\/htb\/9865\" rel=\"bookmark\">Tenofovir studies in children<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Increase of non-AIDS defining cancers in HOPS cohort\" href=\"https:\/\/i-base.info\/htb\/9863\" rel=\"bookmark\">Increase of non-AIDS defining cancers in HOPS cohort<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to HIV\/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1\" href=\"https:\/\/i-base.info\/htb\/9861\" rel=\"bookmark\">HIV\/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Epoetin-alfa improves interferon\/ribavirin-associated anaemia\" href=\"https:\/\/i-base.info\/htb\/9859\" rel=\"bookmark\">Epoetin-alfa improves interferon\/ribavirin-associated anaemia<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>8-11 February 2004, San Francisco About 3,500 doctors, researchers, healthcare workers, journalists and community advocates attended the 11th Conference on Retroviruses and Opportunistic Infections held in San Francisco from 8-11 February, 2004. This meeting is one of the most important &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,58],"class_list":["post-9919","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-conference-index","tag-croi-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9919"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9919\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}